Frequency Therapeutics Announces Phase 1/2 Clinical Trial for Hearing Restoration Drug

Progenitor Cell Activation (PCA) utilizes small molecules to awaken dormant progenitor cells already in the body and reportedly has the opportunity to address numerous degenerative diseases such as hearing loss, demyelinating diseases, skin disorders, and gastrointestinal conditions.